...Xetra:BAYN) for $240 million up front. In 2018, Versant’s Inception 4 start-up was acquired by Ophthotech Corp....

...to treat Leber congenital amaurosis type 10 (LCA10) due to mutations in CEP290. Iveric (formerly Ophthotech Corp....

...HtrA serine peptidase 1 (HTRA1) Preclinical studies suggest HTRA1 inhibitors could help treat dry AMD Ophthotech Corp....

...from animal proof-of-concept to IND-enabling studies. By licensing gene therapy programs at the preclinical stage, Ophthotech...
...others could help overcome the manufacturing bottleneck (see “Academia’s Manufacturing Problem” ). Through its partnerships, Ophthotech...
...apparent that gene therapy was going to play a major role in ophthalmology.” Glenn Sblendorio, Ophthotech...

...to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech Corp....
...serine peptidase 1 (HTRA1) to treat age-related retinal diseases, including dry age-related macular degeneration (AMD). Ophthotech...
...IND for its lead HTRA1 inhibitor in late 2020. Versant gained a 12.5% stake in Ophthotech...

...AAV is designed to knock down mutant RHO expression and deliver a functional replacement gene. Ophthotech...
...universities will also be eligible for royalties in the low single-digit percentages of net sales. Ophthotech...
...Ophthotech has an option to exclusive rights to patents or patent applications from the research. Ophthotech...

...AAV is designed to knock down mutant RHO expression and deliver a functional replacement gene. Ophthotech...
...universities will also be eligible for royalties in the low single-digit percentages of net sales. Ophthotech...
...Ophthotech has an option to exclusive rights to patents or patent applications from the research. Ophthotech...

...the low deal pace for aptamers is largely due to two high-profile clinical disappointments -- Ophthotech Corp.’s...
...Therapeutics Inc., Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Noxxon Pharma N.V., Berlin, Germany Ophthotech Corp....

...BioCentury, Oct. 13, 2017 ). Zimura avacincaptad pegol, a synthetic aptamer that inhibits C5 from Ophthotech Corp....